Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optune + Temozolomide + Pembrolizumab in Newly Diagnosed Glioblastoma
NCT06556563Phase 3Recruiting
- Sponsor
- NovoCure
- Start
- Feb 2025
- Primary completion
- Apr 2029
- Countries
- 12
01
Overview
A Phase 3 trial of pembrolizumab in glioblastoma (GBM), sponsored by NovoCure. Started Feb 2025; status: recruiting.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06556563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06556563.